Xencor, Inc.
XNCRHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeXencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company carries a $831.1M market cap, placing it firmly in the small-cap category. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Market Cap
$831.1M
Beta
0.93
P/E (TTM)
—
P/E (Fwd)
-3.15
EPS (TTM)
$-2.29
EPS (Fwd)
$-3.56
ROE
-29.8%
ROA
-16.2%
Cash
$445.0M
Total Debt
$175.2M
Free CF
-$76.9M
52W Change
23.2%
Annual Financials
Cash vs Debt
With $445.0M in cash and $175.2M in debt, XNCR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$76.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -29.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $275.1M to $125.6M.
With cash comfortably exceeding debt, XNCR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XNCR.